Capecitabine and Oral Cyclophosphamide Combination in Taxane/Antrhracycline Resistant Metastatic Breast Cancer

OZET, Ahmet; UNCU, Dogan; KUZHAN, Okan; KOMURCU, Seref; OZTURK, Mustafa; ARPACI, Fikret; OZTURK, Bekir
June 2011
International Journal of Hematology & Oncology / UHOD: Uluslarar;Jun2011, Vol. 21 Issue 2, p87
Academic Journal
No combination chemotherapy has been shown yet to be more effective in metastatic breast cancer (MBC) patients who did not either respond to taxanes and anthracyclines or recurred thereafter. We aimed to report in short term the effect and toxicity results of capecitabine and oral cyclophosphamide combination in MBC patients with anthracyclin and taxane resistance. Between January and September 2007, totally 11 patients were enrolled. All of them had received anthracyclines and taxanes previously either in metastatic or adjuvant setting. They were given capecitabine (1000 mg/m² bid) and oral cychlophosphamide (30 mg/m² tid) on days 1 to 14 every 3 weeks. Median age of patients was 48 years. The median number of previous chemotherapy lines given was 3. Seven patients had received trastuzumab previously, either as monotherapy or as part of combination chemotherapy. Seven had received capecitabine monotherapy before. Median follow-up was 5 months. The patients received a median of 8 cycles chemotherapy. In 4 patients (36.4%) partial response was obtained. Five patients (45.5%) remained stable, and 2 (18.1%) progressed. Median duration of response was 5 months. At the analysis time, 2 patients were dead. Totally 2 patients (18.1%) had grade 2 leucopenia, 2 (18.1%) had grade 2 hand-foot syndrome, 1 (9.1%) had grade 3 hand-foot syndrome. Capecitabine and oral cyclophosphamide combination is a promising and well tolerated regimen in patients who previously had received taxanes and anthracyclines and in patients with cerbB2 positive tumors who received trastuzumab previously.


Related Articles

  • Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study. Martín, M.; Sánchez-Rovira, P.; Muñoz, M.; Baena-Cañada, J. M.; Mel, J. R.; Margeli, M.; Ramos, M.; Martínez, E.; García-Saenz, J. A.; Casado, A.; Jaén, A. M.; González-Farré, X.; Escudero, M. J.; Rodriguez-Martin, C.; Carrasco, E. // Annals of Oncology;Dec2011, Vol. 22 Issue 12, p2591 

    Background: In order to determine the feasibility of substituting pegylated liposomal doxorubicin (PLD) for doxorubicin in combination with cyclophosphamide and trastuzumab as adjuvant therapy, we conducted a phase II study of the combination as first-line therapy in human epidermal growth...

  • Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Rayson, D.; Suter, T. M.; Jackisch, C.; van der Vegt, S.; Bermejo, B.; van den Bosch, J.; Vivanco, G. L.; van Gent, A. M.; Wildiers, H.; Torres, A.; Provencher, L.; Temizkan, M.; Chirgwin, J.; Canon, J. L.; Ferrandina, G.; Srinivasan, S.; Zhang, L.; Richel, D. J. // Annals of Oncology;Jul2012, Vol. 23 Issue 7, p1780 

    Background The cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) in an adjuvant breast cancer treatment regimen is unknown. Patients and methods Women with resected node-positive or intermediate-risk node-negative HER2 overexpressing breast cancer and baseline...

  • Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro). von Minckwitz, G.; Rezai, M.; Fasching, P. A.; Huober, J.; Tesch, H.; Bauerfeind, I.; Hilfrich, J.; Eidtmann, H.; Gerber, B.; Hanusch, C.; Blohmer, J. U.; Costa, S. D.; Jackisch, C.; Paepke, S.; Schneeweiss, A.; Kümmel, S.; Denkert, C.; Mehta, K.; Loibl, S.; Untch, M. // Annals of Oncology;Jan2014, Vol. 25 Issue 1, p81 

    1495 breast cancer patients received either neoadjuvant EC-Docetaxel or EC-Doxetaxel plus capecitabine or EC-Docetaxel followed by capecitabine and simultaneous trastuzumab in HER2-positive disease. Consistently with pCR rates, adding capecitabine does not improve disease-free survival, but...

  • Ä°nflamatuvar meme kanseri. KESKİN, Serkan; SAİP, Pınar // Turkish Journal of Oncology / Türk Onkoloji Dergisi;Jun2011, Vol. 26 Issue 2, p94 

    Inflammatory breast cancer (IMK) is characterized by breast skin involvement and it is the most aggressive form of breast cancers. IMK constitutes 1-6% of all breast cancers. It appears at early ages than noninflammatory breast cancer. Erythema, "peau d'orange", rapid progression, poor...

  • Cardiac Toxicity of Trastuzumab-Related Regimens in HER2-Overexpressing Breast Cancer. Ewer, Michael S.; O'Shaughnessy, Joyce A. // Clinical Cancer Update;Dec2007, Vol. 1 Issue 1, p22 

    The pivotal trial by Slamon and colleagues of trastuzumab combined with chemotherapy in metastatic breast cancer showed a high incidence of congestive heart failure (CHF) among patients who had received trastuzumab and anthracycline-based therapy simultaneously. As a result, the development of...

  • Herceptin: the evidence. Cameron, Amanda // New Zealand Doctor;3/28/2007, p8 

    The article examines the therapeutic effectiveness of the anti-breast cancer drug Herceptin sequentially after standard chemotherapy or concurrently together with taxane and anthracyclines. The author cites the conclusion reached by Chris Frampton, associate professor at Otago University's...

  • First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study. Allouache, Djelila; Gawande, Sulochana R.; Tubiana-Hulin, Michele; Tubiana-Mathieu, Nicole; Piperno-Neumann, Sophie; Mefti, Fawzia; Bozec, Laurence; Genot, Jean-Yves // BMC Cancer;2005, Vol. 5, p151 

    Background: This phase II study evaluated the efficacy and safety of gemcitabine (G) plus paclitaxel (T) as first-line therapy in recurrent or metastatic breast cancer. Methods: Patients with locally, recurrent or metastatic breast cancer and no prior chemotherapy for metastatic disease received...

  • Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Bengala, C.; Zamagni, C.; Pedrazzoli, P.; Matteucci, P.; Ballestrero, A.; Da Prada, G.; Martino, M.; Rosti, G.; Danova, M.; Bregni, M.; Jovic, G.; Guarneri, V.; Maur, M.; Conte, P. F. // British Journal of Cancer;4/10/2006, Vol. 94 Issue 7, p1016 

    HER-2 overexpression is associated to a poor prognosis in high-risk and metastatic breast cancer (MBC) patients treated with high-dose chemotherapy (HDC). HER-2 status is also a predictive factor and when trastuzumab is administered in combination with or sequentially to chemotherapy, a...

  • Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study. John, Matthias; Hinke, Axel; Stauch, Martina; Wolf, Heiner; Mohr, Benno; Hindenburg, Hans-Joachim; Papke, Jens; Schlosser, Joachim // BMC Cancer;2012, Vol. 12 Issue 1, p165 

    Background: The 3-weekly combination of trastuzumab and paclitaxel has been approved for the treatment of advanced breast cancer based on a large pivotal study. However, mono and combination chemotherapy trials suggest that weekly paclitaxel has a better therapeutic index, especially in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics